Replies to post #164683 on Cytodyn Inc (CYDY)

[misiu143]

So from your own answer, as you see leronlimab is a much more important/better drug , for every stage of this disease then lenzilumab ,

With leronlimab we also down regulate GM-CSF , in between other MOAs .

It is very difficult to find another drug to match even a little all this actions of leronlimab , and all this without one serious side effect..

I researched in the past lenzilumab , and now I follow also , considered even to invest some also there , but the more DD I did the more I staid with leronlimab..

But patients globally need many different drugs , imo lenzilumab is much better then remdesivir , this is why I am surprise why the attachment with this loser drug ,imo.

But for each its own , this is why I don't go to HGEN board to criticize their drug or management , I feel it is not my business to do it...

All IMO.